These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 23617353

  • 21. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
    Wang Y, Zhang J, Gao G, Li X, Zhao C, He Y, Su C, Zhang S, Chen X, Zhang J, Li W, Li B, Zhao J, Hou L, Wu C, Ren S, Zhou C, Zhang J.
    J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
    [Abstract] [Full Text] [Related]

  • 22. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A, Wood K, Salgia R.
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [Abstract] [Full Text] [Related]

  • 23. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
    Gautschi O, Schefer H, Riklin C, Strobel K, Diebold J.
    Onkologie; 2013 Mar; 36(6):342-7. PubMed ID: 23774148
    [Abstract] [Full Text] [Related]

  • 24. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L, Zhang H, Shao W, Chen B.
    Drug Des Devel Ther; 2015 Mar; 9():5491-7. PubMed ID: 26491259
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    Thorne-Nuzzo T, Williams C, Catallini A, Clements J, Singh S, Amberson J, Dickinson K, Gatalica Z, Ho SN, Loftin I, McElhinny A, Towne P.
    J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239
    [Abstract] [Full Text] [Related]

  • 28. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM, Rudin CM.
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Vergne F, Quéré G, Andrieu-Key S, Descourt R, Quintin-Roué I, Talagas M, De Braekeleer M, Marcorelles P, Uguen A.
    Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
    [Abstract] [Full Text] [Related]

  • 31. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O.
    J Clin Oncol; 2015 Mar 20; 33(9):992-9. PubMed ID: 25667280
    [Abstract] [Full Text] [Related]

  • 32. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
    Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlési F.
    Expert Rev Anticancer Ther; 2015 Feb 20; 15(2):225-33. PubMed ID: 25413260
    [Abstract] [Full Text] [Related]

  • 33. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N, Zach L, Liran O, Ilouze M, Bunn PA, Hirsch FR.
    J Thorac Oncol; 2013 Dec 20; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
    Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M.
    Cancer; 2013 Nov 15; 119(22):3968-75. PubMed ID: 24022839
    [Abstract] [Full Text] [Related]

  • 36. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul 15; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 37. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ.
    J Med Econ; 2015 Apr 15; 18(4):312-22. PubMed ID: 25565443
    [Abstract] [Full Text] [Related]

  • 38. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, Leighl NB.
    J Clin Oncol; 2014 Apr 01; 32(10):1012-9. PubMed ID: 24567430
    [Abstract] [Full Text] [Related]

  • 39. Crizotinib resistance: implications for therapeutic strategies.
    Dagogo-Jack I, Shaw AT.
    Ann Oncol; 2016 Sep 01; 27 Suppl 3(Suppl 3):iii42-iii50. PubMed ID: 27573756
    [Abstract] [Full Text] [Related]

  • 40. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
    Kaneda H, Okamoto I, Nakagawa K.
    J Thorac Oncol; 2013 Apr 01; 8(4):e32-3. PubMed ID: 23486271
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.